Approaching the ASCO conference is a good opportunity to take positions in 3 biotechnology companies undervalued. Every year the percentage of return and growth as they approach this time is usually high.Telik, Inc. (TELK), The price to book ratio is 0.50. The company has a drug in Phase 2 TELINTRA ® Trial in Myelodysplastic Syndrome, in Phase 2 Trial in Severe Chronic Neutropenia and Phase 1 Combination Trial with Revlimid in Myelodysplastic Syndrome. He also continues his research in Telcyta ® while in Phase 2 trial using Telcyta ® in MCL, DLBCL & MM.
Columbia Laboratories Inc. (CBRX) The price to sales ratio is 1.76. The company has Prochieve ® 8% (Reduction of Risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy and NDA filed April 2011), COL-1777 Indication: Gynecological Procedures Associated with pain in Phase II and COL -2401 for bacterial vaginosis (Pre-clinical)
BioSante Pharmaceuticals, Inc. (BPAX) The price to book ratio is 4.14. The company has in Phase III LibiGel ® Efficacy Results, Cancer Vaccines: Chronic Myeloid Leukemia CML in Phase II clinical trial, Acute Myeloid Leukemia (AML) in Phase II and Phase II Pancreatic Cancer in, The Pill-Plus ™ is an oral Currently in Development contraceptive in Phase II.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.